SynthesisCancer control : journal of the Moffitt Cancer Center
Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients.
Synthesis in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 57 citations in OpenAlex.
- Emerging roles of POLR2L of RNA polymerase II dynamics and disease mechanisms (Review).Molecular medicine reports · 2026Review
- ATM, BLM, and CDH1 gene co-mutations in a high-grade endometrial stromal sarcoma patient with multiple abdominal cavity metastases: a case report and literature review.BMC geriatrics · 2024Review
- Analysis of prognostic value of lactate metabolism-related genes in ovarian cancer based on bioinformatics.Journal of ovarian research · 2024Article
- Article
- IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer.iScience · 2024Article
- Prognostic value and immunological role of PD-L1 gene in pan-cancer.BMC cancer · 2024Article
- Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?Cancer chemotherapy and pharmacology · 2024Review
- Identification of anoikis-related molecular patterns and the novel risk model to predict prognosis, tumor microenvironment infiltration and immunotherapy response in bladder cancer.Frontiers in immunology · 2024Article
- Bioinformatics identification of a T-cell-related signature for predicting prognosis and drug sensitivity in hepatocellular carcinoma.IET systems biology · 2023Article
- Prognostic and immunotherapeutic significance of immunogenic cell death-related genes in colon adenocarcinoma patients.Scientific reports · 2023Article
- Multi-omics characteristics of tumor-associated macrophages in the tumor microenvironment of gastric cancer and their exploration of immunotherapy potential.Scientific reports · 2023Article
- Nomogram for predicting survival in patients with mucinous breast cancer undergoing chemotherapy and surgery: a population-based study.European journal of medical research · 2023Article
- ceRNA network-regulated COL1A2 high expression correlates with poor prognosis and immune infiltration in colon adenocarcinoma.Scientific reports · 2023Article
- Article
- Construction of a novel signature based on immune-related lncRNA to identify high and low risk pancreatic adenocarcinoma patients.BMC gastroenterology · 2023Article
- Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.BMC medical genomics · 2023Article
- Second primary colorectal cancer in adults: a SEER analysis of incidence and outcomes.BMC gastroenterology · 2023Article
- Knockdown of RBM15 inhibits tumor progression and the JAK-STAT signaling pathway in cervical cancer.BMC cancer · 2023Article
- An integrative bioinformatics investigation and experimental validation of chromobox family in diffuse large B-cell lymphoma.BMC cancer · 2023Article
- Pharmacogenomics: Driving Personalized Medicine.Pharmacological reviews · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveEvidence shows that gene mutation is a significant proportion of genetic factors associated with prostate cancer. The DNA damage response (DDR) is a signal cascade network that aims to maintain genomic integrity in cells. This comprehensive study was performed to determine the link between different DNA damage response gene mutations and prostate cancer. MATERIALS AND
methodsA systematic literature search was performed using PubMed, Web of Science, and Embase. Papers published up to February 1, 2022 were retrieved. The DDR gene mutations associated with prostate cancer were identified by referring to relevant research and review articles. Data of prostate cancer patients from multiple PCa cohorts were obtained from cBioPortal. The OR or HR and 95% CIs were calculated using both fixed-effects models (FEMs) and random-effects models (REMs).
resultsSeventy-four studies were included in this research, and the frequency of 13 DDR genes was examined. Through the analysis of 33 articles that focused on the risk estimates of DDR genes between normal people and PCa patients, DDR genes were found to be more common in prostate cancer patients (OR = 3.6293 95% CI [2.4992; 5.2705]). Also, patients in the mutated group had a worse OS and DFS outcome than those in the unmutated group (
conclusionThese results demonstrate that mutation in any DDR pathway results in a poor prognosis for PCa patients. Furthermore, mutations in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.